News Search Results
Jul 02, 2026, 21:36 ET Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence
CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Peng Wang as Chief Operating
More news about: Nona Biosciences
Jul 02, 2026, 20:00 ET 騰盛博藥公佈用於慢性乙型肝炎治療的IIb期ENRICH及ENHANCE研究的治療結束頂線數據
Margolis博士表示：「上述初步的治療結束時數據為評估ENRICH與ENHANCE研究設計的相對表現提供了重要依據。儘管仍需更長期隨訪以評估HBsAg清除的持久性，但目前觀察到的數據連同既往多項研究的治療結束時及治療後結果具有較高一致性，支持ENRICH設計作為註冊性研究的優選方案。我們期待在今年晚些時候分享更為完整的數據。」如此前披露，鑒於與Vir Biotechnology, Inc.之間正在進行的仲裁，且雙方仲裁獲得結果或就相關申索達成和解方案，其內容及時間均存在不確定性，公司認為elebsiran項目的未來存在不確定性。尤其是，除非及直至仲裁中的申索獲得令人滿意的解決，本公司將無法投資進行任何含elebsiran的乙型肝炎聯合治療方案的III期臨床研究。公司將繼續評估相關進展，評估其對elebsiran項目繼續推進前景的影響，並將根據相關規定適時向本公司股東及公眾作出更新。有關騰盛博藥乙肝候選藥物的更多信息，請訪問：
More news about: 騰盛博藥生物科技有限公司
Jul 02, 2026, 20:00 ET Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
the Greater China territory from Vir Biotechnology, Inc. in 2020. In May 2024, the CDE of China's NMPA granted elebsiran Breakthrough Therapy Designation.About Brii BioBrii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to improve
More news about: Brii Biosciences Limited
Jul 02, 2026, 14:41 ET Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical
More news about: Northwest Biotherapeutics, Inc.
Jul 02, 2026, 14:17 ET Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical
More news about: Northwest Biotherapeutics, Inc.
Jul 02, 2026, 10:46 ET Global DNA Diagnostics Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight
Early detection enables timely medical intervention and improved patient management.Rising Investments in Biotechnology and Genomics Research: Pharmaceutical, biotechnology, and research organizations are investing heavily in genomic studies and biomarker discovery. These activities are creating
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
Astex Pharmaceuticals), ArriVent BioPharma, Shanghai Allist Pharmaceuticals, Innovent Biologics, Takeda Pharmaceutical, Apollomics, Avistone Biotechnology, and others, are developing new non-small cell lung cancer treatment drugs that can be available in the non-small cell lung cancer market in the
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 10:30 ET Label Identification Technologies Market worth $2.87 billion by 2031 | MarketsandMarkets™
identification market as laboratories increasingly focus on automation, sample traceability, and data accuracy across clinical diagnostics, pharmaceutical, biotechnology, and research applications. A key trend is the growing adoption of advanced 2D barcode scanning technologies that read data matrix and QR codes
More news about: MarketsandMarkets
Jul 02, 2026, 08:42 ET O'Shaughnessy Ventures Funds Researcher Classifying Chronic Pain
aging-related diseases. As a teenager, he worked on CRISPR research at Yale and later at the University of Wisconsin-Madison. He then joined Gordian Biotechnology, a longevity startup in San Francisco, where he searched for drugs to treat heart failure and osteoarthritis. In 2025, he began developing his chronic
More news about: O'Shaughnessy Ventures
Jul 02, 2026, 07:05 ET New Nature Biotechnology Article Highlights the Need for Cell-Cell Interaction Data in AI Biology
Nature Biotechnology perspective article, authored by researchers from UCLA and collaborating institutions, is bringing renewed attention to cell-cell interaction
More news about: Partillion Bioscience
Jul 02, 2026, 06:30 ET Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
LEXINGTON, Mass., July 2, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced that results from the cholangiocarcinoma cohort of the eNRGy trial (NCT02912949) have been published in the
More news about: Partner Therapeutics, Inc.
Jul 01, 2026, 22:16 ET Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
www.takeda.com.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jul 01, 2026, 20:05 ET Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza
More news about: Nona Biosciences
Jul 01, 2026, 19:05 ET Siddharth Mittal Appointed as Managing Director & CEO of Syngene International
NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 8,300 employees including 5,700+ scientists, brings
More news about: Syngene International
Jul 01, 2026, 15:15 ET Eisenhower Fellowships names 2026 Innovative Entrepreneurs Program Fellows
demonstrated success in building enterprises that generate measurable economic and social impact in diverse fields that include technology, healthcare, biotechnology, agriculture, clean energy, workforce development and finance.
More news about: Eisenhower Fellowships
Jul 01, 2026, 14:37 ET AOB Pharma and Biorasi to Partner to run Phase 2b in Moderate to Severe Acne
CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- AOB Pharma, Inc. ("AOBiome"), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions, announced that it has partnered with Biorasi, a Clinical Research Organization to start the process
More news about: AOBiome Therapeutics
Jul 01, 2026, 13:12 ET Covenant Makes Follow-On Investment in Hill Research, Citing Fourfold Revenue Growth and Accelerating Market Adoption
Research is positioned to grow an additional 5 to 8 times, supported by accelerating adoption of its platform, TriClick, across pharmaceutical, biotechnology, and clinical research organizations.Why Covenant Invested Again Covenant's investment framework prioritizes structure, discipline,
More news about: Covenant Venture Capital
Jul 01, 2026, 11:26 ET Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
range of $76 million to $80 million. The Company attributed the revised outlook, in part, to market uncertainties affecting pharmaceutical and biotechnology customers, including budget reductions, project cancellations, and delays.Following this announcement, Simulations Plus stock declined more
More news about: Johnson Fistel, PLLP
Jul 01, 2026, 11:21 ET MGI Tech Launches Go Spatial in Europe and Expands STOmics Partner Network at STOC 2026
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various
More news about: MGI Tech Co., Ltd.
Jul 01, 2026, 10:46 ET Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight
witnessing robust growth, driven by the increasing global burden of cancer and the rising demand for preclinical oncology research. Pharmaceutical and biotechnology companies are increasingly outsourcing in-vivo studies to specialized CROs to accelerate drug development while reducing operational costs. Advancements
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
Designation (BTD) to plixorafenib for treating adult patients with BRAF V600E-mutated high-grade glioma (HGG).In March 2026, Siren Biotechnology announced that the FDA had approved the Investigational New Drug (IND) application filed by the University of California, San Francisco, enabling
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 09:04 ET Aramore Selected as a 2026 BeautyMatter NEXT50
commitment to innovation and research-backed formulations.ABOUT ARAMORE:Aramore was founded at the intersection of biotechnology and beauty by a team of experts united by a shared belief: that the future of skincare lies in supporting skin performance at the cellular level,
More news about: ARAMORE Skincare
Jul 01, 2026, 09:03 ET Dr. Marc Hurlbert Begins Tenure as Chief Executive Officer of the National Kidney Foundation
addressing critical public health challenges. He is recognized for building collaborations across patient advocacy, academia, government, and the biotechnology and pharmaceutical sectors to drive innovation and improve health outcomes."This is a defining moment for NKF," Dr. Hurlbert said. "Science
More news about: National Kidney Foundation
Jul 01, 2026, 08:59 ET Charles Huang: The True Meaning of Business Success Is Giving Back
driven by immigrants and innovation, and California remains one of the world's most dynamic innovation ecosystems."He points to technology, biotechnology, entertainment, agriculture, and advanced manufacturing as the industries that collectively underpin California's long-term economic strength.Success
More news about: Pasaca Capital Inc.
Jul 01, 2026, 08:52 ET ProBio's AAV Manufacturing Excellence Powers UC Irvine and GlyTR Therapeutics First‑in‑Class pan-cancer CAR‑T Program
medschool.uci.edu.About GlyTR TherapeuticsGlyTR Therapeutics is an early‑stage biotechnology company developing a new class of anti‑cancer immunotherapeutics and CAR‑T cell therapies. Its GlyTR platform generates both bispecific proteins
More news about: ProBio Inc.